Table: Santen Pharm -9-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

08/02/2024 06:00

Feb 8 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2023        Dec 31, 2022     Mar 31, 2024 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              222.83              199.79           302.00    
                   (+11.5 pct)         (+2.0 pct)       (+8.2 pct)  
  Operating           36.16            loss 10.15          41.00    
  Pretax              33.56            loss 11.59          38.30    
  Net                 26.61            loss 16.06                   
  EPS Basic         72.26 yen        loss 41.13 yen      80.64 yen  
  EPS Diluted       72.05 yen        loss 41.13 yen                 
  Ann Div                               32.00 yen        33.00 yen  
  -Q2 Div           16.00 yen           16.00 yen                   
  -Q4 Div                               16.00 yen        17.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T